5i Research Weekly Rockets and Duds
This week's 5i Research Rockets 
and Duds 
Soleno Therapeutics Inc. SLNO 
Soleno got FDA approval of its Vykat extended-release tablets for the treatment of hyperphagia with Prader-Willi syndrome. Shares rose 46% for the week. Cantor said the full label approval is a 'best case scenario' and the research firm raised its target to $123. The stock is now up 60% this year and up 68% over 52 weeks. I think I better go to the doctor. A key feature of Prader-Willi syndrome is a feeling of being hungry all the time. This sounds a lot like what I've got.
When the market is going to hell in a handbasket, it is refreshing to see that actual fundamentals still matter for some investors. CNXC rose 27% last week on the heels of--you guessed it--actual good earnings results. Quarterly results were solid and the company, which uses technology to solve customers' 'business challenges', whatever that means, also upped its 2025 guidance slightly. 
WOR is another stock with good fundamentals that actually is getting rewarded. WOR rose 27% last week after the maker of building and consumer products reported net sales and earnings that beat estimates. The company noted that recent tariff announcements are creating some uncertainty, but it is 'well-positioned' for growth and possible M&A activity. 
NFE: We don't run a LNG business, but we've been to Jamaica a few times. NFE fell 21% last week on news it sold its Jamaican businesses for $1.055 billion cash. We don't know about you, but if we had a Jamaican subsidiary it would be the last thing to be sold, so we could go do some 'work' in the country in the winter. NFE shares fell 21% on the news. Turns out the company simply needed the money. It has $9.5 billion in debt, and shares are down 70% in the past year. It is expected to lose money again this year. 
Has your daughter been asking for an AI-run, robotic pony? There are advantages to a robot pet, of course, and they do not have to be curbed. Imagine your daughter's birthday joy with her own AI horse! Alas, it is not to be. Pony AI is a company developing autonomous driving solutions. It has been in our Rockets and Duds report before. Shares fell 29% last week as the tech sector continues to get decimated. The company received its first permit in China and reported record revenue last week, but this was not enough to keep investors interested. The stock is now down 31% since its November US IPO. 
Unlock the Power of Informed Investing with 5i Research!
DIY investing doesn't have to mean going it alone. At 5i Research, we're your trusted partner in navigating the stock market. Our platform offers comprehensive stock and market research, empowering you to make smart investment decisions.
- Investor Q&A: Have burning questions? Get answers from our team of experts and fellow investors in our dedicated Q&A section.
- Research Reports: With over 60 meticulously researched Canadian stocks, our reports offer in-depth analysis, giving you the confidence to invest wisely.
- Model Portfolios, Alerts, Forums, Portfolio Tracking, and Much More...
Analysts of 5i Research responsible for this report do not have a financial or other interest in securities mentioned. The i2i Fund does not have a financial or other interest in securities mentioned.
Comments
Login to post a comment.